Amgen's late-stage weight-loss drug MariTide is getting ready to enter the final stages of testing as the company enrolls its ...

Amgen shares are trading lower Monday afternoon. The company released full results from part one of its phase two study of ...

Amgen's long-acting experimental obesity drug MariTide needs to be given at a low starting dose to limit side effects like ...

Amgen's weight-loss drug MariTide had a successful Phase 2 trial so the company is expanding development plans to study its use for heart disease and sleep apnea.

Amgen's experimental obesity drug MariTide showed promising weight loss results with fewer side effects, according to a ...

Amgen Inc. ( NASDAQ: AMGN) Special Call (IR Call) Conference June 23, 2025 5:30 PM ET Justin Claeys - Vice President of Investor Relations James Bradner - Executive Vice President of Research & ...

Amgen's experimental drug MariTide shows potential for significant weight loss in obese patients, despite notable side ...

A new trial has found that a weight loss drug taken monthly helps people lose 20 percent of their body weight. Weight loss ...

Amgen (NASDAQ:AMGN) today announced full results from Part 1 of the Phase 2 study of MariTide (maridebart cafraglutide, formerly AMG 133), a long-acting, peptide-antibody conjugate subcutaneously ...

Amgen is expanding development plans for its weight-loss drug MariTide to study its use for heart disease and sleep apnea.

A new experimental drug meant to be taken just once a month could lead to “substantial weight reduction” within a year and ...

Amgen’s monthly obesity candidate led to substantial weight loss but a high rate of side effects and discontinuations in a ...